d8-TT2-32 acetate | CAS#147159-51-1

MedKoo Cat#: 556045 | Name: d8-TT2-32 acetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

d8-TT2-32 is perphenylanine-deuterated TT2-32 analog. TT2-32, also known as TLN-232 and CAP232, is a somatostatin structural derivative with antitumor activity. TT-232 inhibited tyrosine kinase activity of tumor cell lines and this inhibition correlated well with the inhibition of cell proliferation of a large number of cancer cell lines in vitro and reduces the size of different tumors in animal models in vivo. The antitumor efficacy of TT-232 has been found to be associated with the induction of apoptosis in tumor cells, resulting in highly selective elimination of tumor tissue. TT-232 was found to be devoid of GH release inhibitory activity but to possess strong antitumor effects. It binds with a high affinity to SSTR1 and SSTR4. This compound was also found to inhibit inflammation in a number of experimental models.

Chemical Structure

d8-TT2-32 acetate

CAS#d8-TT2-32 acetate

Theoretical Analysis

MedKoo Cat#: 556045

Name: d8-TT2-32 acetate

CAS#: d8-TT2-32 acetate

Chemical Formula: C47H54D8N10O11S2

Exact Mass:

Molecular Weight: 1015.24

Elemental Analysis: C, 55.60; H, 6.95; N, 13.80; O, 17.33; S, 6.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

d8-TT2-32 acetate; deuterated labeled-TT2-32; TT2-32; TT2 32; TT232; TT-232; TT 232; CAP 232; CAP-232; CAP232; TLN-232; TLN 232; TLN232;

IUPAC/Chemical Name

(4R,7S,10R,13S,16R)-10-((1H-indol-3-yl)methyl)-16-((R)-2-amino-3-(phenyl-d5)propanamido-2,3,3-d3)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-7-(4-aminobutyl)-13-(4-hydroxybenzyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecane-4-carboxamide acetate

InChi Key

DPXYLBGOBOVJQG-ZSWOJWCMSA-N

InChi Code

InChI=1S/C45H58N10O9S2.C2H4O2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46;1-2(3)4/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64);1H3,(H,3,4)/t25-,31-,33+,34+,35-,36+,37+,38+;/m1./s1/i2D,3D,4D,9D,10D,19D2,31D;

SMILES Code

O=C([C@@H](NC([C@H](CCCCN)NC([C@@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)NC4=O)=O)=O)=O)CSSC[C@@H]4NC([C@]([2H])(N)C([2H])(C5=C(C([2H])=C(C([2H])=C5[2H])[2H])[2H])[2H])=O)N[C@@H]([C@H](O)C)C(N)=O.CC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,015.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Varona L, Noguera JL, Casellas J, de Hijas MM, Rosas JP, Ibáñez-Escriche N. A cross-specific multiplicative binomial recursive model for the analysis of perinatal mortality in a diallel cross among three varieties of Iberian pig. Sci Rep. 2020 Dec 3;10(1):21190. doi: 10.1038/s41598-020-78346-7. PMID: 33273670; PMCID: PMC7712833. 2: Sun C, Liu M, Zhang W, Wang S, Qian G, Wang M, Zhang G. Overexpression of enolase 2 is associated with worsened prognosis and increased glycikolysis in papillary renal cell carcinoma. J Cell Physiol. 2021 May;236(5):3821-3831. doi: 10.1002/jcp.30130. Epub 2020 Nov 1. PMID: 33135164. 3: Kuriyama I, Miyazaki A, Tsuda Y, Yoshida H, Mizushina Y. Inhibitory effect of novel somatostatin peptide analogues on human cancer cell growth based on the selective inhibition of DNA polymerase β. Bioorg Med Chem. 2013 Jan 15;21(2):403-11. doi: 10.1016/j.bmc.2012.11.024. Epub 2012 Nov 29. PMID: 23266186. 4: Jung Y, Oh SH, Witek RP, Petersen BE. Somatostatin stimulates the migration of hepatic oval cells in the injured rat liver. Liver Int. 2012 Feb;32(2):312-20. doi: 10.1111/j.1478-3231.2011.02642.x. Epub 2011 Sep 14. PMID: 22098068; PMCID: PMC3253984. 5: Szolcsányi J, Pintér E, Helyes Z, Petho G. Inhibition of the function of TRPV1-expressing nociceptive sensory neurons by somatostatin 4 receptor agonism: mechanism and therapeutical implications. Curr Top Med Chem. 2011;11(17):2253-63. doi: 10.2174/156802611796904852. PMID: 21671870. 6: Kuriyama I, Miyazaki A, Tsuda Y, Yokoi T, Okada Y, Takeuchi T, Sugawara F, Yoshida H, Mizushina Y. Inhibitory effect of somatostatin Peptide analogues on DNA polymerase activity and human cancer cell proliferation. Anticancer Res. 2010 Dec;30(12):4841-9. PMID: 21187461. 7: Tejeda M, Gaal D, Hullán L, Csuka O, Schwab R, Szokoloczi O, Kéri GY. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. Anticancer Res. 2008 Sep-Oct;28(5A):2769-74. PMID: 19035308. 8: Miyazaki A, Tsuda Y, Fukushima S, Yokoi T, Vántus T, Bökönyi G, Szabó E, Horváth A, Kéri G, Okada Y. Synthesis of somatostatin analogues containing C-terminal adamantane and their antiproliferative properties. J Med Chem. 2008 Aug 28;51(16):5121-4. doi: 10.1021/jm701599w. Epub 2008 Aug 5. PMID: 18680358. 9: Tejeda M, Gaál D, Hullán L, Schwab R, Szokoloczi O, Kéri G. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models. Anticancer Res. 2007 Nov-Dec;27(6B):4015-9. PMID: 18225564. 10: Elekes K, Helyes Z, Kereskai L, Sándor K, Pintér E, Pozsgai G, Tékus V, Bánvölgyi A, Németh J, Szuts T, Kéri G, Szolcsányi J. Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse. Eur J Pharmacol. 2008 Jan 14;578(2-3):313-22. doi: 10.1016/j.ejphar.2007.09.033. Epub 2007 Oct 5. PMID: 17961545. 11: Steták A, Veress R, Ovádi J, Csermely P, Kéri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007 Feb 15;67(4):1602-8. doi: 10.1158/0008-5472.CAN-06-2870. PMID: 17308100. 12: Tejeda M, Gaál D, Hullán L, Hegymegi-Barakonyi B, Kéri G. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Anticancer Res. 2006 Sep-Oct;26(5A):3477-83. PMID: 17094470. 13: Tejeda M, Gaál D, Hullán L, Csuka O, Schwab R, Szokoloczi O, Kéri G. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. Anticancer Res. 2006 Jul-Aug;26(4B):3011-5. PMID: 16886628. 14: Szokolóczi O, Schwab R, Peták I, Orfi L, Pap A, Eberle AN, Szüts T, Kéril G. TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. J Recept Signal Transduct Res. 2005;25(4-6):217-35. doi: 10.1080/10799890500464621. PMID: 16393913. 15: Tejeda M, Gaál D, Csuka O, Kéri G. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Res. 2005 Jan-Feb;25(1A):325-30. PMID: 15816555. 16: Szolcsányi J, Bölcskei K, Szabó A, Pintér E, Petho G, Elekes K, Börzsei R, Almási R, Szuts T, Kéri G, Helyes Z. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. Eur J Pharmacol. 2004 Sep 13;498(1-3):103-9. doi: 10.1016/j.ejphar.2004.07.085. PMID: 15363982. 17: Helyes Z, Szabó A, Németh J, Jakab B, Pintér E, Bánvölgyi A, Kereskai L, Kéri G, Szolcsányi J. Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. Arthritis Rheum. 2004 May;50(5):1677-85. doi: 10.1002/art.20184. PMID: 15146439. 18: Simon A, Czajlik A, Perczel A, Kéri G, Nyikos L, Emri Z, Kardos J. Binding crevice for TT-232 in a homology model of type 1 somatostatin receptor. Biochem Biophys Res Commun. 2004 Apr 16;316(4):1059-64. doi: 10.1016/j.bbrc.2004.02.161. PMID: 15044092. 19: Kéri G, Racz G, Magyar K, Orfi L, Horváth A, Schwab R, Hegymegi BB, Szende B. Pro-apoptotic and anti-apoptotic molecules affecting pathways of signal transduction. Ann N Y Acad Sci. 2003 Dec;1010:109-12. doi: 10.1196/annals.1299.018. PMID: 15033704. 20: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. PMID: 14988742.